To explore the effect of a nutrition and lifestyle intervention on quality of life for patients suffering from PuLmonary Arterial Hypertension.
ID
Source
Brief title
Condition
- Heart failures
- Pulmonary vascular disorders
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
To explore the effect of a nutrition and lifestyle intervention for
PAH-patients on quality of life.
Secondary outcome
- Perform a systematic analyses of nutritional status. Is nutritional status
associated with clinical worsening or RV function in PAH?
- Determine the effect of nutritional education alone, and the additional
effect of a nutritional intervention in PAH.
- Determine which nutritional intervention is most effective. Which diet is
associated with the largest improvement in quality of life and best compliance
in PAH?
Background summary
Nutrition and lifestyle interventions are currently not implanted in usual
clinical care of PAH-patients. Mainly because there is little known on the
relation between pathology, nutrition and lifestyle. Patients who suffer from
Pulmonary Arterial Hypertension feel insecure about their nutrition and
lifestyle. We hypothesize that an intervention on nutrition and lifestyle can
improve the patients* quality of life.
Study objective
To explore the effect of a nutrition and lifestyle intervention on quality of
life for patients suffering from PuLmonary Arterial Hypertension.
Study design
Investigator initiated intervention study.
Intervention
Every subject will have the option to wear a Fitbit during this study, and than
has to wear it day and night, during the entire study. With the Fitbit we want
to track the general wellbeing: daily exercise, heartrate and the sleeping
pattern. Fitbit has an secured research platform that collects data from
internet connected devices: Fitabase. This cloud-based software is fully
hosted, keeps data private and has been used in over 400 studies. The subjects
will be randomly assigned to the intervention and control group. Subsequently,
patients in the intervention group will be randomly assigned to the MedDASH
diet or MedDASHfat diet.
First, we will perform baseline measurements in the study and control group to
determine the nutritional status.
Subsequently, patients of the intervention group will receive nutritional
education. In 8 plenary masterclasses information is provided on the use of
sugar, fluid, salt, herbs, amino acids, fatty acids, vegetables, alcohol,
product labels and medication interactions with nutrition. The masterclasses,
with a duration of three hours for every session, will be given in small groups
(maximum of ten per group) and the patients will receive homework with
nutrition and lifestyle assignments. Two weeks after the last masterclass the
whole study group will participate in a cooking masterclass on location, to
implement the obtained knowledge.
After the nutritional education, the subjects of the intervention group will be
randomly assigned to a MedDASH diet or a MedDASHfat diet. The MedDASH diet is
comprised of 55% carbohydrates, 25% amino acids, 20% fatty acids, whereas the
MedDASHfat diet is comprised of 10% carbohydrates, 25% amino acids, 65% fatty
acids. Both groups will receive a list of products they can consume daily,
daily menu examples and precepts for the diet and lifestyle (for example: only
eat carbohydrates once a day, don*t use blue light after 10 p.m., make a list
before you go grocery shopping). After 3 months of diet, efficacy is tested by
comparing quality of life, RV function, exercise capacity and general
well-being between the 2 diets and the control group. After 6 months,
compliance is analysed.
Study burden and risks
The burden for the patient exists of 12 extra visits to the hospital and
contact moments, over a period of 11 months, as well compliance to the diet and
lifestyle. The radiation risk form the DEXAscan is minimal, with 0,05 mSV in
the total study There is a minimum risk in participation.
Boelelaan 1117
Amsterdam 1081HV
NL
Boelelaan 1117
Amsterdam 1081HV
NL
Listed location countries
Age
Inclusion criteria
Diagnoses of idiopathic PAH, hereditary PAH or drug related PAH
Age between 18 and 80
NYHA II or III and stable for at least three months, measured with 6MWT <10%
differnce
Self-sufficient and/or compliance from partner and/or family
Creatinine > 30 ml/min
Able to understand and willing to sign the Informed Consent Form
Exclusion criteria
Pregnant subjects
Fat percentage < 10% > 55%
One or more of the following comorbidities: diabetes mellitus type one or two,
clinical relevant hypothyroid
Known history of noncompliance considering therapies
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
CCMO | NL66484.029.18 |